Literature DB >> 17511799

Early identification of persistent trophoblastic disease with serum hCG concentration ratios.

N E van Trommel1, H Ngo Duc, L F A G Massuger, C P T Schijf, C G J Sweep, C M G Thomas.   

Abstract

The objective of the present study was to assess the diagnostic potential of serum human chorionic gonadotropin (hCG) ratios obtained at different intervals after evacuation of hydatidiform mole to diagnose persistent trophoblastic disease (PTD) and to compare its diagnostic accuracy with the current FIGO 2000 criteria as a gold standard. We calculated hCG ratios from serum hCG concentrations of 204 patients (86 with and 118 without PTD) registered with the Dutch Central Registry for Hydatidiform Moles between 1977-2004. The hCG ratios obtained in week 1, 3, and 5 after evacuation identified, respectively, 20%, 52%, and 79% of patients with PTD (median: 3.0 weeks) at the 95% specificity level, while FIGO 2000 criteria identified, respectively, 0%, 16%, and 66% (median: 4.7 weeks). It is concluded that a serum hCG ratio identifies patients with PTD approximately 2 weeks earlier than the internationally accepted FIGO 2000 criteria and identifies more than 75% of patients who develop PTD by the fifth week after evacuation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17511799     DOI: 10.1111/j.1525-1438.2007.00993.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  2 in total

1.  Serum human chorionic gonadotropin ratios for the detection of etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine resistance in high-risk gestational trophoblastic neoplasia.

Authors:  Nathapol Sirimusika; Sathana Boonyapipat
Journal:  Health Sci Rep       Date:  2022-07-20

2.  Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.

Authors:  Y M Hoeijmakers; Fcgj Sweep; Car Lok; P B Ottevanger
Journal:  BJOG       Date:  2020-03-31       Impact factor: 6.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.